DR info

臨床試験数 : 42 / 薬物数 : 33 - (DrugBank : 11) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 123

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

ABC008
   Abcuro, Inc.
      2021   Phase 1   NCT04659031   Australia;
ADSVF
   Assistance Publique - Hôpitaux de Paris
      2021   Phase 1   NCT05032131   -
Alemtuzumab (Campath)
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 2   NCT00079768   United States;
Anakinra
   Karolinska Institutet
      2003   Phase 2/Phase 3   NCT01165008   Sweden;
Arimoclomol
   Orphazyme
      2019   Phase 3   NCT04049097   United Kingdom;United States;
      2017   Phase 2   NCT02753530   United Kingdom;United States;
   Richard Barohn, MD
      2008   Phase 2/Phase 3   NCT00769860   United Kingdom;United States;
   UCL - The Joint UCLH/UCL Comprehensive Biomedical Research Unit
      2009   Phase 2   EUCTR2008-008208-42-GB   United Kingdom;
Arimoclomol citrate
   Orphazyme A/S
      2019   Phase 3   EUCTR2019-000749-11-GB   United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-004903-33-GB   United Kingdom;United States;
BRX-345
   Orphazyme A/S
      2019   Phase 3   EUCTR2019-000749-11-GB   United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2017-004903-33-GB   United Kingdom;United States;
   UCL - The Joint UCLH/UCL Comprehensive Biomedical Research Unit
      2009   Phase 2   EUCTR2008-008208-42-GB   United Kingdom;
BYM338
   NOVARTIS FARMA S.P.A.
      2015   Phase 3   EUCTR2015-001411-12-IT   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States;
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-000705-23-IT   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States;
   Novartis Pharma K.K.
      2015   Phase 2-3   JPRN-JapicCTI-153078   -
      2013   Phase 2-3   JPRN-JapicCTI-132365   -
   Novartis Pharma Services AG
      2015   Phase 3   EUCTR2015-001411-12-NL   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001411-12-GB   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001411-12-FR   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001411-12-DK   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001411-12-BE   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-000705-23-GB   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-000705-23-DK   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-000705-23-DE   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States;
      2014   -   EUCTR2013-000705-23-NL   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States;
      2014   -   EUCTR2013-000705-23-BE   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States;
   Novartis Pharmaceuticals
      2011   Phase 2   NCT01423110   United States;
BYM338 (Bimagrumab)
   Novartis Pharmaceuticals
      2014   Phase 2/Phase 3   NCT02250443   United States;
BYM338/bimagrumab
   Novartis Pharmaceuticals
      2013   Phase 2/Phase 3   NCT01925209   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States;
Bimagrumab
   NOVARTIS FARMA S.P.A.
      2015   Phase 3   EUCTR2015-001411-12-IT   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States;
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-000705-23-IT   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States;
   Novartis Pharma K.K.
      2015   Phase 2-3   JPRN-JapicCTI-153078   -
      2013   Phase 2-3   JPRN-JapicCTI-132365   -
   Novartis Pharma Services AG
      2015   Phase 3   EUCTR2015-001411-12-NL   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001411-12-GB   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001411-12-FR   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001411-12-DK   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-001411-12-BE   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States;
   Novartis Pharmaceuticals
      2015   Phase 3   NCT02573467   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States;
Blood draw for optional genetic exome sequencing
   LMU Klinikum
      2022   -   NCT05272969   Germany;
Calcium
   LMU Klinikum
      2022   -   NCT05272969   Germany;
Care as usual
   University of Southern Denmark
      2015   -   NCT02317094   Denmark;
Creatine
   LMU Klinikum
      2022   -   NCT05272969   Germany;
Etanercept
   Washington University School of Medicine
      2005   Phase 0   NCT00802815   United States;
FLEBOGAMMA
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2007   -   EUCTR2006-005942-35-IT   Italy;
Gamma Globulin
   National Institute of Neurological Disorders and Stroke (NINDS)
      1990   Phase 2   NCT00001261   United States;
Genetic test: ACE polymorphism
   LMU Klinikum
      2022   -   NCT05272969   Germany;
Genetic test: ACTN3 polymorphism
   LMU Klinikum
      2022   -   NCT05272969   Germany;
Immunoglobulins, normal human, for intravascular adm.
   ISTITUTO NEUROLOGICO CARLO BESTA
      2007   -   EUCTR2007-004359-12-IT   Italy;
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2007   -   EUCTR2006-005942-35-IT   Italy;
Magnesium
   LMU Klinikum
      2022   -   NCT05272969   Germany;
Natalizumab
   Phoenix Neurological Associates, LTD
      2013   Phase 1   NCT02483845   United States;
Phenylbutyrate Oral Tablet
   University of Kansas Medical Center
      2020   Phase 1   NCT04421677   United States;
Phosphate
   LMU Klinikum
      2022   -   NCT05272969   Germany;
Pioglitazone
   Johns Hopkins University
      2018   Phase 1   NCT03440034   United States;
RAAV1.CMV.huFollistatin344
   Nationwide Children's Hospital
      2012   Phase 1   NCT01519349   United States;
REGN2477+REGN1033
   Regeneron Pharmaceuticals
      2019   Phase 2   NCT03710941   -
Rapamycin
   Institut National de la Santé Et de la Recherche Médicale, France
      2015   Phase 2/Phase 3   NCT02481453   France;
Simvastatin
   ISTITUTO NEUROLOGICO CARLO BESTA
      2007   -   EUCTR2007-004359-12-IT   Italy;
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2007   -   EUCTR2006-005942-35-IT   Italy;
Sirolimus
   University of Kansas Medical Center
      2022   Phase 3   NCT04789070   United States;
Vitamin D
   LMU Klinikum
      2022   -   NCT05272969   Germany;
Xeomin
   Rigshospitalet
      2014   Phase 2   EUCTR2014-002210-23-DK   Denmark;